By comparison, efforts to apply the endometrial carcinoma molecular classifier—the PROMISE algorithm—have not identified a sizeable proportion of excellent prognosis EnOC patients20–22; POLE-mutated tumours are reportedly associated with around 90% 10-year overall patient survival, but account for only 3.5% of cases, limiting implementation of POLE as a prognostic marker. This evidence concerns the gene POLE and endometrial carcinoma.